The RET proto-oncogene is often activated through somatic rearrangements in papillary thyroid carcinomas (PTCs). Three main rearranged forms of RET have been described: RET/PTC1 and RET/PTC3, which arise from a paracentric inversion and RET/PTC2, which originates from a 10 : 17 translocation. We previously developed a dual-color FISH test to detect these RET rearrangements in interphase nuclei of thyroid lesions. This approach allowed us to detect a novel translocation involving the RET region, which was not detectable by RT ± PCR with speci®c primers for known rearrangements. A combination of RT ± PCR and RACE analyses ®nally led to the identi®cation of the fusion gene, which involves the 5' portion of PCM-1, a gene coding for a centrosomal protein with distinct cell cycle distribution, and the RET tyrosine kinase (TK) domain. FISH analysis con®rmed the chromosomal localization of PCM-1 on chromosome 8p21-22, a region commonly deleted in several tumors. Immunohistochemistry, using an antibody speci®c for the C-terminal portion of PCM-1 showed that the protein level is drastically decreased and its subcellular localization is altered in thyroid tumor tissue with respect to normal thyroid. However, heterozygosity is retained for seven microsatellite markers in the 8p21-22 region, suggesting that the nonrearranged PCM-1 allele is not lost and that the translocation is balanced. Oncogene (2000) 19, 4236 ± 4242.
Introduction
The RET proto-oncogene, which maps to the long arm of chromosome 10 at band q11.2, can be rearranged by somatic chromosomal mutations in papillary thyroid carcinomas. These rearrangements (inversions or translocations) always involve intron 11 of RET and lead to the juxtaposition of its intracellular tyrosine kinase (TK) domain to the 5' portion of dierent donor genes constitutively expressed in the thyroid (see review by Pasini et al., 1996) . By fusing with the intracellular domain of RET, these genes contribute a novel amino-terminal portion which makes RET activation ligand independent.
Three main rearranged forms of RET have been described in PTCs: RET/PTC1 (Grieco et al., 1990) , RET/PTC2 (Bongarzone et al., 1993) and RET/PTC3 (Bongarzone et al., 1994) . RET/PTC1 is formed by an intrachromosomal rearrangement fusing the RET TK domain to a gene designated H4 (D10S170), whose function is still unknown (Grieco et al., 1990) . In RET/PTC2, the catalytic domain of RET is fused to the 5' terminal sequence of the R1a regulatory subunit of protein kinase A (Bongarzone et al., 1993) , while in RET/PTC3 the donor is ELE1, a gene whose product interacts with the ligand binding domain of the androgen receptor (Alen et al., 1999) . Although these genes have dierent functions, they share the same ubiquitous expression pattern. Four novel types of rearrangements, named RET/ PTC5, RET/PTC6, RET/PTC7 and RET/ELKS (Klugbauer et al., 1998; Klugbauer and Rabes, 1999; Nakata et al., 1999) have recently been identi®ed.
The frequency of RET/PTC rearrangements described in the literature varies widely among dierent adult patient series (Bongarzone et al., 1996; Sugg et al., 1996) . To clarify this point and to see whether this wide distribution could be due to technical limitations, we developed a dual-color FISH approach to detect RET rearrangements in interphase nuclei of thyroid lesions (Cinti et al., 2000) . This led to the identi®cation of a PTC tumor that carried a chromosomal abnormality involving the RET region, which could not be detected by RT ± PCR with primers for RET/PTC1, PTC2, PTC3 and PTC5. We describe here that this sporadic tumor showed a translocation of RET, which did not involve chromosome 17, as in the case of RET/PTC2. The recent identi®cation of new types of rearrangements and the fact that several studies report the expression of the RET TK domain by RT ± PCR in PTCs characterized by the absence of any known rearrangement (Nikiforov et al., 1997) , suggest the involvement of yet unknown genes in the activation of RET. We therefore decided to further investigate the PTC sample that carried the novel type of RET translocation. In the present study we show that the translocated portion of RET is often associated with the centromere of chromosome 8 in interphase nuclei, and that the RET TK domain is highly expressed in this tumor. We then found that the 5' portion of PCM-1, a gene localized on chromosome 8 and not yet known to be involved in human tumorigenesis, is fused with the RET TK domain. We also show that PCM-1 is well expressed in the normal thyroid, but its expression and intracellular sub-localization in the tumor is altered.
Results

Detection of RET rearrangement by FISH
In a previous study we had analysed a total of 91 thyroid tumor specimens (69 PTCs and 22 benign lesions) (Cinti et al., 2000) by two-color interphase FISH using a pool of three overlapping cosmid probes that encompass the RET gene along with an a-satellite probe that speci®cally recognizes the centromere of chromosome 10. Among the PTCs, one of the samples that showed a RET translocation resulted negative for RET/PTC2 and RET/ PTC5 upon RT ± PCR analysis (Figure 1a) . To investigate whether this tumor carried a translocation involving chromosome 17 (as in the case of RET/PTC2), we cohybridized the nuclei with RET and an a-satellite probe speci®c for the centromere of chromosome 17. The two centromeric signals were randomly distributed in the nuclei and were not associated with the RET signal, like in the case of 10:17 translocations, suggesting that the cells might carry a yet unidenti®ed translocation ( Figure  1b) .
In order to determine which chromosome carried the translocated portion of the RET gene, we cohybridized the tumor nuclei with a panel of centromeric probes and the RET cosmids. If the translocated RET is localized in the vicinity of a chromosome centromere, then one of the two centromeric signals should appear associated with the RET signal. We used centromeric probes for chromosomes 2, 6, 7, 8, 9, 11, 12, 15, 18 . One of the RET signals was found to be consistently associated with the centromere of chromosome 8 (Figure 1c ).
RET TK expression
Thirteen PTCs, one neuroectodermal tumor cell line (SK-N-MC), two PTC cell lines (PTC1 and TPC1), two lymphoblastoid cell lines and two normal thyroid tissues were screened for RET TK activation using RT ± PCR. We also ampli®ed the b-actin as an internal control. All PTCs have been previously screened by FISH and RT ± PCR for the presence of RET rearrangements (Cinti et al., 2000) . Six of the tumors and the two PTC cell lines showed evidence for an obviously enhanced TK product proven by the presence of PCR product of the predicted size ( Figure  2a ). Among the positive tumors, one of the samples carried the yet unknown type of rearrangement identi®ed by FISH (Figure 2a ; lane 1). Comparable intensities of bands were observed for the above tumor and the thyroid carcinoma cell lines, known to carry an activated RET.
Identification of a novel fusion gene
FISH and RT ± PCR results strongly indicate the presence of an unknown type of rearrangement in the tumor described above. The 5'-RACE strategy that has been described in detail by Klugbauer et al. (1996) , was applied to the RNA of this tumor. 5'-RACE experiments resulted in many PCR products of dierent size. Subsequent hybridization with a RET TK probe con®rmed the presence of several bands containing the TK domain of RET. The most prominent band was directly sequenced, and this sequence was deposited in the EMBL nucleotide sequence database (accession number: AJ297349). Database searching showed that the RET TK domain was rearranged with a gene not yet known to be involved in human tumor development (Figure 3a) . The sequence was identical to the 5' portion of the gene PCM-1, which encodes the centrosome autoantigen pericentriolar material 1 (Balczon et al., 1994) . The open reading frame of PCM-1 comprises 6072 nucleotides and the molecular mass of the protein is 228.7 kD. The large coding region may explain the diculty of amplifying the full-length fusion transcript by RACE ± PCR. The breakpoint within the RET sequence was at the same position as in previously described RET/PTC1, RET/PTC2 and RET/PTC3 cases. In this case the two genes share the same 4 bp sequence at the fusion point. A large portion of the PCM-1 gene (4826 nucleotides) contributes to the fusion gene. The predicted size of the chimeric protein is 2011 aminoacids and its molecular mass has been estimated to be 227.4 kD. Moreover, the protein presents several potential coiled coil domains. CDNA linear maps and protein structures of PCM-1, RET and the fusion gene are schematically shown in Figure 3b .
Identification of fusion products in the cDNA of the tumor PCR reactions were performed to prove the actual presence of the fusion transcript obtained by 5'-RACE in the tumor. The expected PCR product was obtained using primers for RET/PCM-1 (Figure 2c ). This was Figure 1 Translocation involving the RET proto-oncogene in nuclei extracted from frozen thyroid tumor of the same patient. RET cosmids and chromosome 8 YAC 812g7 were labeled with biotin and detected with¯uorescein-conjugated avidin (green); asatellite probes were labeled with digoxigenin and detected with anti-digoxigenin-rhodamine Fab fragments (red). (a) RET cosmids and an a-satellite probe which speci®cally recognizes chromosome 10 were cohybridized to the tumor nuclei. The arrow indicates the RET region which is translocated to another chromosome. (b) RET was co-hybridized with an a-satellite probe for chromosome 17. The signals are randomly distributed excluding the presence of the rearrangement RET/PTC2, which involves chromosome 17. (c) RET was co-hybridized with an asatellite probe for chromosome 8. The arrow indicates the RET signal that is often observed in the vicinity of centromere 8. (d) YAC harboring the PCM-1 gene maps on 8p21-22. DAPI counterstain (left) and inverse DAPI counterstain (right) also con®rmed by direct sequencing (data not shown). We could not detect a reciprocal transcript using primers for the presence of a reciprocal rearrangement (data not shown).
PCM-1 expression in normal and tumor thyroid tissues PCM-1 has previously been found expressed in testis, heart and skeletal muscle (Chinen et al., 1996) . We performed RT ± PCR to test the expression level of PCM-1 in normal and tumor thyroid samples and in lymphocytes as control. PCM-1 was highly expressed in all normal thyroid samples and its expression level was comparable to that found in lymphocytes ( Figure  2b ). Thirty PTCs, including the tumor carrying the RET/PCM-1 rearrangement, also showed a similar pattern of expression (Figure 2b ). PCM-1 expression in the latter case is probably due to the intact copy of PCM-1 or to normal follicular cell contamination in the tumor sample. Since RET is not expressed in thyroid follicular cells, the fusion of RET with PCM-1 is most probably the cause of the expression of the TK domain of RET in the thyroid tumor tissue.
Immunohistochemistry in RET/PCM-1 tumor
Immunohistochemistry was performed using an antibody generated against the carboxyterminal part of the PCM-1 protein (Balczon et al., 1994) .
Tumor and normal tissue sections from the same patient were analysed in parallel. We observed high levels of PCM-1 expression in the cytoplasm of all normal follicular cells (Figure 4a ). The protein was also present in the cytoplasm of tumor cells, but at a considerably lower level. Interestingly, a dierent expression pattern was observed in tumor cells (Figure 4b ). While PCM-1 was homogeneously distributed throughout the cell cytoplasm in normal cells, its sublocalization was restricted to the supranuclear apical portion in tumor cells. Tumor cells which were not in contact with follicles did not show any immunoreactivity for PCM-1. A moderate staining was also observed in muscular and endothelial cells. Altogether, the expression pattern of PCM-1 is clearly dierent in normal and tumor tissue.
Mapping and chromosomal localization of PCM-1 Three overlapping CEPH YAC clones have previously been mapped to the 8p commonly deleted region (Chinen et al., 1996) . We ®rst established that PCM-1 was carried only by YAC 812g7, by performing a PCR with PCM-1 primers (data not shown). We subsequently con®rmed the localization of PCM-1 on 8p21.3-p22 by hybridizing normal lymphocyte chromosomes with the YAC probe that harbored the gene (Figure 1d) . 
LOH analysis
DNA from the RET/PCM-1 thyroid tumor and matched normal thyroid DNA were analysed for LOH of seven microsatellite markers from chromosomal band 8p21-22. The results are presented in Figure  5 . The physical map order of the microsatellite loci analysed was obtained from the Genome database. All markers were informative and heterozygosity was retained in all cases. This suggests that no loss of material has occurred during the translocation event originating RET/PCM-1 and no apparent gross deletion is present in the homologous chromosome 8.
Discussion
Several indications suggest the existence of yet unknown RET rearrangements in PTC. In this study, we show that interphase FISH is a good tool for the detection of new chromosomal abnormalities involving the RET region. Using a combination of RT ± PCR and RACE analyses we identi®ed a novel type of rearrangement which involves the fusion of RET to the 5'-end of the PCM-1 gene. To date, most RET rearrangements have been ®rst identi®ed in Chernobyl radiation-induced tumors. In the present study RET/ PCM-1 was found in a patient who had been exposed to external radiation for the therapeutic treatment of an oral cancer. Recently, several novel types of rearrangements, which are all the result of interchromosomal translocations have been detected (Klugbauer et al., 1998; Klugbauer and Rabes, 1999; Nakata et al., 1999) , indicating that the same mechanism may bring RET under the control of various yet unknown donor genes. Although it is premature to estimate the real frequency of RET translocations in thyroid tumors, paracentric inversions of chromosome 10 (like in RET/ PTC1 and RET/PTC3) seem to occur quite frequently. This suggests that thyrocytes may be characterized by a high instability of this region of chromosome 10. A preferential involvement of chromosome 10 was observed in lymphocytes of children exposed to the Chernobyl fallout (Scarpato et al., 1997) . Moreover, we detected partial and complete trisomies of the long arm of chromosome 10 in several PTC samples (Cinti et al., 2000) . The RET/PCM-1 fusion has never been observed in tumors so far. This type of rearrangement is probably rare since we detected it only once in our tumor series. However, we cannot exclude that it may have been missed during screenings of PTC series by RT ± PCR using primers for PTC1, PTC2, PTC3.
PCM-1 has previously been mapped to chromosome 8p21.3-22 (Ohata et al., 1994) , and this has been con®rmed in the present study by FISH analysis. Although 8p21-22 is a region commonly deleted in hepatocellular, colorectal, non-small cell lung carcinoma (Emi et al., 1992) , prostate cancer (Bergerheim et al., 1991) and bladder cancer (Knowles et al., 1993) , this is the ®rst report suggesting the involvement of PCM-1 in the process of oncogenic activation. The frequent 8p loss in a variety of tumors implies the presence of one or more putative tumor suppressor genes in this region. PCM-1 fragments have, in fact, been isolated by exon-trapping of the commonly deleted region, in an attempt to identify tumor suppressor gene candidates (Ohata et al., 1994) . However, the PCM-1 cDNA clones were ®rst obtained by screening a human fetal liver cDNA expression library using a human autoimmune centrosome antiserum (Balczon et al., 1994) . PCM-1 encodes a 228 kD centrosomal protein that exhibits a distinct cell cycledependent association with the centrosome complex. Our results show that PCM-1 is well expressed both in lymphocytes and in normal thyroid. Even though no systematic expression study in various tissue samples has ever been carried out, the data from Chinen et al. (1996) and ours suggest an ubiquitous expression of PCM-1. This is consistent with the fact that the other RET donor genes are all ubiquitously expressed and lead thus to the unscheduled expression of the RET TK in thyroid, as we observed in the RET/PCM-1 tumor. In addition, it has been proposed that oligomerization of the fusion protein may serve as a common mechanism for oncogenic activation of other receptor tyrosine kinases in thyroid tumors. Both RET/ PTC1 and RET/PTC2 form dimers in vivo, and RET/ PTC1 dimerization is essential for its tyrosine hyperphosphorylation and its transforming activity (Tong et al., 1997; Durick et al., 1995) . Further experiments are necessary to demonstrate whether the aminoterminal portion of PCM-1, that shows several potential coiled-coil domains, can form oligomers. It has already been proposed that the interaction between PCM-1 and the Huntigtin-associated protein 1 (HAP1) might be mediated by the formation of coiled-coil elements (Engelender et al., 1997) .
During centrosome replication in somatic mammalian cells, that occurs only once per cell cycle, PCM-1 is targeted to the centrosome via transport along microtubules (Balczon et al., 1999) . More recent investigations showed that the injection of antibodies against PCM-1 into fertilized mouse eggs had no eect on microtubule assembly or organization. Instead, the microinjected antibodies induced cell cycle arrest while PCM-1 and the other centrosome autoantigens were displaced from the centrosome region (Balczon, personal communication) . The chromosomal PCM-1 localization and the demonstration that its activity is associated with cell cycle progression ®ts nicely with the possibility that PCM-1 may be a tumor suppressor gene. If this hypothesis were con®rmed by further experimental evidence, the RET/PCM-1 would involve the inactivation of a putative tumor suppressor gene and the activation of an oncogene within the same fused gene. Such mechanism has previously been proposed for the TEL/AML translocation in childhood acute lymphoblastic leukemis (Raynaud et al., 1996) . In this case the translocation was often associated with the deletion of the second TEL allele.
The decreased level of PCM-1 protein observed in tumor cells may re¯ect the inactivation of one of the alleles. The retention of heterozygosity through the 8p21-22 chromosomal region indicates that the wild type PCM-1 allele is not deleted and that no genetic material seems to be lost during the translocation event. However, this does not explain the clear change in the protein level and its sublocalization in tumor cells. The highly localized distribution of PCM-1 in tumor cells suggests that the function of the protein may be altered. One possibility is that the protein might be active through dimerization or tetramerization. The coexistence of the wild type PCM-1 and the rearranged form might then aect its stability or function.
Recent data suggest that RET rearrangements may play a role in early tumorigenesis and do not seem to be associated with tumor progression (Sugg et al., 1998; Tallini et al., 1998; Corvi et al., in preparation) . It is thus likely, that synergistic and additive eects of RET and other genes are important for the development and progression of thyroid carcinoma. Further studies are now necessary to elucidate the role of PCM-1 in tumorigenesis.
Materials and methods
Thyroid tissues and cell lines
Normal and tumor thyroid samples were obtained from patients that were undergoing surgery at the Clinique Endocrinologique de l'HoÃ pital de l'Antiquaille in Lyon. The tumor that carried the new type of rearrangement was from a female patient, aged 44 at the time of surgery, who underwent thyroidectomy and had previously received ionizing radiations for the treatment of an oropharyngeal tumor. The tumor was a mixed PTC variant with papillary and solid trabecular structures, and TNM classi®cation T4N1Mo.
Tumor cell lines PTC1 and TPC1 were from Dr Pierotti (Milano) and the two lymphoblastoid cell lines were established in our laboratory.
Nuclei extraction from frozen tissues
A piece of frozen tissue was dissociated with a scalpel in ethanol 70% and then incubated for 10 min at 378C in a pepsin solution (0.1 mg/ml of pepsin in 10 mM HCl). The suspension was dropped on normal slides. The slides were air dried, ®xed in Carnoy's, and dehydrated in an ethanol series.
Probes
A mixture of three cosmids R1, E5, F2, covering about 100 kb of the RET genomic region (Pasini et al., 1995) was used. Among these, the E5 cosmid contained intron 11. In addition, we used a-satellite probes speci®c for chromosomes 2, 6, 7, 8, 9, 10, 15, 17 and 18 (kindly provided by Mariano Rocchi, University of Bari, Italy) and YAC clone 812g7, 931a1, and 946c9 (CEPH) which map on 8p21.3-22 (Chinen et al., 1996) . The YAC which carried PCM-1 was identi®ed by PCR with P3 and P9 primers. Cosmids and YACs were labeled with biotin-16-dUTP while a-satellite probes were labeled with digoxigenin (Roche Diagnostics, Boehringer Mannheim, Germany) by nick translation as described by Langer et al. (1981) .
The RET TK probe for Southern blot was produced by PCR ampli®cation of the RET cDNA clone.
Fluorescence in situ hybridization (FISH)
FISH on interphase nuclei was performed as previously described (Barker and Schwab, 1993; Corvi et al., 1994) . Probe concentration was 15 ng/ml for the pool of RET cosmids and 20 ng/ml for the YAC. Repetitive sequences were suppressed with a 10-fold and 50-fold excess of Cot-1 DNA, respectively (Roche Diagnostics). The slides were evaluated on a Zeiss Axiophot epi¯uorescence microscope and for each preparation we analysed about 300 interphase nuclei.
mRNA isolation and RT ± PCR
Total RNA was extracted with TRIZOL Reagent (Gibco BRL). cDNA synthesis and RT ± PCR were carried out using GeneAmp RNA PCR Kit (PERKIN ELMER) according to the manufacturer's instruction, with the addition of Platinum Taq polymerase (Gibco BRL) to the PCR reactions.
We used primers: P1 and P2 for ampli®cation of the RET TK domain; P3 and P4 for ampli®cation of PCM-1; P3 and P5 for ampli®cation of the rearrangement in the tumor; and P6 and P7 for ampli®cation of the reciprocal rearrangement (see Table 1 for sequences).
Both the precise amount of total RNA added to the reaction and its quality are dicult to assess. We therefore used the transcripts of the gene coding for b-actin as the endogenous RNA control. Standard curves were constructed by plotting the cycle number versus the change in the intensity of b-actin and PCM-1 transcripts. This allowed us to estimate the number of PCR cycles necessary in order to be in a situation of proportionality. We used 28 cycles for bactin and 35 for PCM-1.
5'-RACE and sequencing
Ampli®cation of unknown 5'-cDNA ends was performed using the 5'-RACE system according to the method described by the manufacturers (Roche Diagnostics, Boehringer Mannheim GmbH). Brie¯y, tumor total RNA (4 ml of 40 ml total) was reverse transcribed with an antisense primer to the RET TK domain. Then terminal transferase was used to add a homopolymeric A-tail to the 3'-end of the ®rst-strand cDNA. The resulting tailed cDNA was ampli®ed in a nested PCR approach using an oligo dT-anchor oligonucleotide and a second PCR anchor oligonucleotide provided by the kit as forward primers and two RET-speci®c oligonucleotides as reverse primers. The primers used were those described by Klugbauer et al., 1998 . Bands were cut from the gel and the DNA was puri®ed using the Quiaquick gel extraction kit (Quiagen). Cycle sequencing of DNA was performed according to protocols for the ABI PRISM 377 DNA sequencer (Perkin Elmer Applied Biosystems) with P8 primer (Table 1) . Southern blot was performed as follows: PCR product was electrophoresed on a 1.8% agarose gel, transferred to a nylon membrane and hybridized with a RET TK DNA probe.
Homology search and computer assisted analysis
The BLAST program (Altshul et al., 1990) was used for nucleotide and protein sequence homology searches in the EST, DNA and protein databases. Protein molecular mass and coiled coil domain structures were estimated using the Expasy proteomics tools (Compute PI/MW and Coils softwares; http://www.expasy.ch/tools/).
Immunohistochemistry
Five-micrometer sections were cut from paran-embedded blocks. After dewaxing and inhibition of endogenous peroxidase, sections were treated by microwave (750 W) for 15 min in citrate buer (pH 6.0). Immunohistochemistry was performed using the Vectastain Elite ABC kit (Vector laboratories). Anti-PCM-1 antibody (Balczon et al., 1994) was anity puri®ed as described by Bao et al. (1998) and used at a 1 : 500 dilution.
LOH analysis
Normal and tumor thyroid DNA from the RET/PCM-1 patient were assessed for allelic loss at 8p21-22 by microsatellite analysis. Seven microsatellite markers spanning approximately 17 cM were examined ( Figure 5 ). The 5'-nucleotide of one of each primer pair was labeled with ā uorescent dye (FAM, HEX or TET). Microsatellite markers were analysed after ampli®cation by PCR on a DNA Sequencer model 377 (Applied Biosystems). Allelic loss was scored using the Genescan Analysis software by comparing the allele ratios in normal and tumor DNAs. A dierence in allele ratios greater than 30% was scored as allele loss.
Abbreviations PTC, papillary thyroid carcinoma; TK, tyrosine kinase; FISH,¯uorescence in situ hybridization; LOH, loss of heterozygosity. 5'-GGAGCCAGGGTCGGATTCCAGTTA-3' P2 5'-CCGCTCAGGAGGAATCCCAGGATA-3' P3 5'-AGTGAAGTTTCTACCATCC-3' P4 5'-GCACAAGATTGTATCACTCC-3' P5 5'-GGCGTTCTCTTTCAGCATCT-3' P6 5'-CGTATTTGGCTGAC-3' P7 5'-GCCAGTGAATCCTGTAAT-3' P8 5'-AATGTTGATGTCTTGGGTCTCC-3' P9 5'GTCCAGCTGCTGAGTATCA-3'
